Provectus Biopharmaceuticals, Inc.
Balance Sheet
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Equivalents | $1.2M | $223.9K | $251.3K | $72.5K | $385.9K | $390.4K | $307.4K | $187.5K |
| Accounts Receivable | — | — | — | — | — | — | — | — |
| Inventory | — | — | — | — | — | — | — | — |
| Total Current Assets | $1.4M | $460.4K | $567.9K | $278.0K | $568.3K | $649.5K | $976.8K | $760.0K |
| Property, Plant & Equipment | $2.1K | $2.5K | $3.0K | $3.5K | $3.9K | $4.4K | $4.9K | $5.3K |
| Goodwill | — | — | — | — | — | — | — | — |
| Intangible Assets (Excl. Goodwill) | — | — | — | — | — | — | — | — |
| Total Assets | $1.5M | $577.6K | $697.5K | $419.9K | $722.4K | $666.3K | $1.0M | $802.0K |
| Liabilities | ||||||||
| Accounts Payable | $932.0K | $815.3K | $716.2K | $1.2M | $1.3M | $744.0K | $1.1M | $1.4M |
| Total Current Liabilities | $7.7M | $7.2M | $6.9M | $6.5M | $6.5M | $5.7M | $7.0M | $6.2M |
| Long-Term Debt | — | — | — | — | — | — | — | — |
| Total Liabilities | $7.8M | $7.3M | $7.0M | $6.6M | $6.6M | $5.7M | $7.0M | $6.2M |
| Stockholders' Equity | ||||||||
| Retained Earnings | $-265.1M | $-264.1M | $-262.9M | $-261.7M | $-260.4M | $-258.6M | $-257.4M | $-255.1M |
| Total Stockholders' Equity | $-6.3M | $-6.7M | $-6.3M | $-6.2M | $-5.9M | $-5.1M | $-6.0M | $-5.4M |